|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.02 USD | +0.07% |
|
-.--% | +71.30% |
Company Valuation: RAPT Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 485 | 1,085 | 672 | 854.7 | 213.2 | 1,794 | 1,794 | - |
| Change | - | 123.77% | -38.08% | 27.19% | -75.05% | 741.39% | 0% | - |
| Enterprise Value (EV) | 373.5 | 895.6 | 422.9 | 695.9 | -17.82 | 1,794 | 1,794 | 1,794 |
| Change | - | 139.81% | -52.77% | 64.53% | -102.56% | 10,167.55% | 0% | 0% |
| P/E | -9.02x | -14.5x | -7.67x | -8.15x | -0.5x | - | - | - |
| PBR | 4.7x | 5.82x | 2.77x | 5.81x | 0.39x | - | - | - |
| PEG | - | -0.9x | -3.88x | -0.4x | -0.11x | - | - | - |
| Capitalization / Revenue | 96.2x | 285x | 440x | - | - | - | - | - |
| EV / Revenue | 0x | 0x | 0x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - | -18,104,290x | -12,616,984x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -17.52 | -20.24 | -20.64 | -24.4 | -25.52 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.042 | 3.813 | 1.527 | - | - | - | - | - |
| EBITDA | -52.09 | -68.21 | -84.75 | -125.8 | -134.9 | - | - | - |
| EBIT | -53.21 | -69.21 | -85.8 | -127.1 | -136.1 | - | -99.1 | -142.2 |
| Net income | -52.89 | -69.2 | -83.84 | -116.8 | -129.9 | - | - | - |
| Net Debt | -111.5 | -189.7 | -249.1 | -158.9 | -231.1 | - | - | - |
| Reference price 2 | 158.00 | 293.84 | 158.40 | 198.80 | 12.64 | 58.02 | 58.02 | 58.02 |
| Nbr of stocks (in thousands) | 3,069 | 3,693 | 4,243 | 4,300 | 16,870 | 30,923 | 30,923 | - |
| Announcement Date | 3/11/21 | 3/10/22 | 3/14/23 | 3/7/24 | 3/6/25 | - | - | - |
1USD in Million2
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 1.79B | |
| 20.56x | 7.11x | 14.62x | 1.42% | 68.12B | |
| 31.44x | 8.03x | 24.45x | 0.05% | 55.18B | |
| -82.67x | 15.62x | -80.83x | -.--% | 28.63B | |
| -14.87x | 5.23x | -6.82x | -.--% | 23.53B | |
| 30.46x | 5.97x | 15.8x | -.--% | 23.99B | |
| 25.58x | 4.78x | 15.97x | -.--% | 18.45B | |
| 47.61x | 19.33x | 49.78x | 0.08% | 15.83B | |
| -1250.29x | 38.99x | -15519.34x | -.--% | 16.44B | |
| 17.06x | 4.95x | 11.57x | -.--% | 13.4B | |
| Average | -130.57x | 12.22x | -1,719.42x | 0.17% | 26.54B | |
| Weighted average by Cap. | -68.10x | 10.40x | -962.22x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RAPT Stock
- Valuation RAPT Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
